Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment.

Lebdai S, Chevrot A, Doizi S, Pradere B, Delongchamps NB, Benchikh A, Cornu JN, Della Negra E, Fourmarier M, Misraï V, Theveniaud PE, Descazeaud A, Robert G; CTMH-AFU group.

World J Urol. 2018 Jul 2. doi: 10.1007/s00345-018-2368-6. [Epub ahead of print] Review.

PMID:
29967947
2.

Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).

Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, Apfelbeck M, Gaillac B, Gratzke C, Stief C, Azzouzi AR.

Eur Urol Focus. 2018 Apr 13. pii: S2405-4569(18)30092-0. doi: 10.1016/j.euf.2018.04.003. [Epub ahead of print]

PMID:
29661587
3.

Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder.

Leroux PA, Brassart E, Lebdai S, Azzouzi AR, Bigot P, Carrouget J.

World J Urol. 2018 Sep;36(9):1455-1460. doi: 10.1007/s00345-018-2296-5. Epub 2018 Apr 9.

PMID:
29633085
4.

Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.

Kim K, Watson PA, Lebdai S, Jebiwott S, Somma AJ, La Rosa S, Mehta D, Murray KS, Lilja H, Ulmert D, Monette S, Scherz A, Coleman JA.

Clin Cancer Res. 2018 May 15;24(10):2408-2416. doi: 10.1158/1078-0432.CCR-17-3474. Epub 2018 Feb 20.

PMID:
29463549
5.

Fatty acid profile in peri-prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and Caucasian patients.

Figiel S, Pinault M, Domingo I, Guimaraes C, Guibon R, Besson P, Tavernier E, Blanchet P, Multigner L, Bruyère F, Haillot O, Mathieu R, Vincendeau S, Rioux-Leclercq N, Lebdai S, Azzouzi AR, Perrouin-Verbe MA, Fournier G, Doucet L, Rigaud J, Renaudin K, Mahéo K, Fromont G.

Eur J Cancer. 2018 Mar;91:107-115. doi: 10.1016/j.ejca.2017.12.017.

PMID:
29413967
6.

Mesalazine: A Novel Etiology For Drug-Induced Urinary Calculi.

Corbery B, Lebdai S, Borojeni S, Bigot P, Azzouzi AR, Culty T.

Urol J. 2018 May 3;15(3):132-133. doi: 10.22037/uj.v0i0.3902.

7.

Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.

Lebdai S, Mathieu R, Leger J, Haillot O, Vincendeau S, Rioux-Leclercq N, Fournier G, Perrouin-Verbe MA, Doucet L, Azzouzi AR, Rigaud J, Renaudin K, Charles T, Bruyere F, Fromont G.

Urol Oncol. 2018 Feb;36(2):80.e17-80.e24. doi: 10.1016/j.urolonc.2017.09.026. Epub 2017 Nov 16.

PMID:
29153942
8.

[Focal therapies: An alternative option for low-risk prostate cancer management?]

Lebdai S, Lunelli L, Bigot P, Cussenot O, Azzouzi AR.

Presse Med. 2017 Oct;46(10):935-939. doi: 10.1016/j.lpm.2017.09.012. Epub 2017 Oct 12. French.

PMID:
29031683
9.

Geriatric Assessment Can Predict Outcomes of Endoscopic Surgery for Benign Prostatic Hyperplasia in Elderly Patients.

Pichon T, Lebdai S, Launay CP, Collet N, Chautard D, Cerruti A, Hoarau N, Brassart E, Bigot P, Beauchet O, Azzouzi AR, Culty T.

J Endourol. 2017 Nov;31(11):1195-1202. doi: 10.1089/end.2017.0325.

PMID:
28903581
10.

Evaluation of bleeding risk in patients on anticoagulation for mechanical cardiac valve operated for benign prostatic obstruction.

Gardic S, Misrai V, Azzouzi AR, Campeggi A, Cornu JN, Taille A, Lebdai S, Mathieu R, Robert G, Descazeaud A.

Prog Urol. 2017 Sep;27(10):559-563. doi: 10.1016/j.purol.2017.05.012. Epub 2017 Jun 24.

PMID:
28651993
11.

Perioperative and economic analysis of surgical treatments for benign prostatic hyperplasia: A study of the French committee on LUT.

Mathieu R, Lebdai S, Cornu JN, Benchikh A, Azzouzi AR, Delongchamps NB, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Misrai V, de La Taille A, Robert G, Descazeaud A.

Prog Urol. 2017 May;27(6):362-368. doi: 10.1016/j.purol.2017.03.010. Epub 2017 May 8.

PMID:
28495071
12.

Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.

Lebdai S, Bigot P, Leroux PA, Berthelot LP, Maulaz P, Azzouzi AR.

J Urol. 2017 Aug;198(2):335-344. doi: 10.1016/j.juro.2017.03.119. Epub 2017 Mar 18.

PMID:
28322857
13.

How Did We Obtain Complete Remission in Patients Who Had Metastatic Renal Cancer in the Era of Targeted Therapies?

Brécheteau F, Lebdai S, Carrouget J, Lebigot J, Nedelcu C, Rousselet MC, Baize N, Azzouzi AR, Bigot P.

Ann Surg Oncol. 2017 Feb;24(2):369-374. doi: 10.1245/s10434-016-5587-3. Epub 2016 Sep 23.

PMID:
27663564
14.

Impact of retrograde flexible ureteroscopy and intracorporeal lithotripsy on kidney functional outcomes.

Hoarau N, Martin F, Lebdai S, Chautard D, Culty T, Azzouzi AR, Bigot P.

Int Braz J Urol. 2015 Sep-Oct;41(5):920-6. doi: 10.1590/S1677-5538.IBJU.2014.0402.

15.

[Medicoeconomic aspects of benign prostatic hyperplasia medical treatment].

Lebdai S, Azzouzi AR, Delongchamps NB, Benchikh A, Campeggi A, Cornu JN, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2016 Feb;26(2):129-36. doi: 10.1016/j.purol.2015.10.010. Epub 2015 Nov 28. Review. French.

PMID:
26643518
16.

Comment avons-nous obtenu des rémissions complètes chez les patients atteints d'un cancer du rein métastatique depuis l'utilisation des thérapies ciblées ?

Brécheteau F, Carrouget J, Lebdai S, Azzouzi A, Bigot P.

Prog Urol. 2015 Nov;25(13):802-3. doi: 10.1016/j.purol.2015.08.173. French. No abstract available.

PMID:
26544367
17.

Impact de l'urétéroscopie souple et de la lithotripsie intrarénales sur la fonction rénale.

Hoarau N, Martin F, Lebdai S, Chautard D, Culty T, Azzouzi A, Bigot P.

Prog Urol. 2014 Nov;24(13):887. doi: 10.1016/j.purol.2014.08.226. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461752
18.

Le cancer de vessie chez le sujet jeune, une étude de population française.

Compérat E, Larré S, Neuzillet Y, Vordos D, Soulié M, Azzouzi A, Pignot G, Durand X, Quintens H, Houede N, Jeglischi S, El Bakri A, Bigot P, Lebdai S, Rouprêt M, Pfister C.

Prog Urol. 2014 Nov;24(13):846. doi: 10.1016/j.purol.2014.08.140. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461667
19.

Accessibilité prévisible au post-internat d'urologie jusqu'en 2016.

Celhay O, Brichart N, Audenet F, Capon G, Dariane C, Fiard G, Lebdaï S, Madec F, Maurin C, Sanson S, Rizk J, Tanchoux C, Thibault F, Terrasa J, Murez T, Terrier J.

Prog Urol. 2014 Nov;24(13):836. doi: 10.1016/j.purol.2014.08.116. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461644
20.

Le laser doit-il supplanter les techniques classiques dans le traitement de l'HBP des patients sous AVK porteurs de valves cardiaques mécaniques?

Gardic S, Azzouzi A, Campeggi A, Cornu J, De la Taille A, Lebdai S, Mathieu R, Misrai V, Robert G, Descazeaud A.

Prog Urol. 2014 Nov;24(13):792. doi: 10.1016/j.purol.2014.08.023. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461550
21.

[Editorial comment to: Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients].

Bigot P, Lebdai S, Azzouzi AR.

Prog Urol. 2015 Dec;25(16):1169-70. doi: 10.1016/j.purol.2015.09.001. Epub 2015 Oct 9. French. No abstract available.

PMID:
26455777
22.

What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?

Lebdai S, Basset V, Branchereau J, de La Taille A, Flamand V, Lebret T, Murez T, Neuzillet Y, Ploussard G, Audenet F.

World J Urol. 2016 May;34(5):617-24. doi: 10.1007/s00345-015-1687-0. Epub 2015 Sep 15. Review.

PMID:
26373956
23.

Posterior Spinal Cord Syndrome after Flexible Ureteroscopy for Kidney Stones.

Carrouget J, Ammi M, Nedelcu C, Cassereau J, Lebdai S, Azzouzi AR, Bigot P.

Urol Int. 2016;96(1):116-8. doi: 10.1159/000439138. Epub 2015 Sep 5.

PMID:
26340745
24.

Early results and complications of prostatic arterial embolization for benign prostatic hyperplasia.

Lebdai S, Delongchamps NB, Sapoval M, Robert G, Amouyal G, Thiounn N, Karsenty G, Ruffion A, de La Taille A, Descazeaud A, Mathieu R.

World J Urol. 2016 May;34(5):625-32. doi: 10.1007/s00345-015-1665-6. Epub 2015 Aug 15. Review.

PMID:
26276151
25.

[Serious and unexpected complications of benign prostatic obstruction surgery: Results of the LUTS Committee survey from urologists of the French Urological Association].

Misraï V, Barry Delongchamps N, Lebdai S, Azzouzi AR, Benchikh A, Cornu JN, Dumonceau O, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2015 Sep;25(10):583-9. doi: 10.1016/j.purol.2015.06.006. Epub 2015 Jul 7. French.

PMID:
26159052
26.

Editorial Comment to Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.

Bigot P, Lebdai S, Azzouzi AR.

Int J Urol. 2015 Aug;22(8):740-1. doi: 10.1111/iju.12818. Epub 2015 May 26. No abstract available.

27.

Acute renal colic during pregnancy: management and predictive factors.

N'gamba M, Lebdai S, Hasting C, Panayotopoulos P, Ammi M, Sentilhes L, Descamps P, Azzouzi AR, Bigot P.

Can J Urol. 2015 Apr;22(2):7732-8.

PMID:
25891338
28.

[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].

Descazeaud A, Barry Delongchamps N, Cornu JN, Azzouzi AR, Buchon D, Benchikh A, Coloby P, Dumonceau O, Fourmarier M, Haillot O, Lebdai S, Mathieu R, Misrai V, Saussine C, de La Taille A, Robert G; Comité des troubles mictionnels de l’homme de l’Association française d’urologie (CTMH-AFU).

Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2. French.

PMID:
25841758
29.

Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.

Azzouzi AR, Lebdai S, Benzaghou F, Stief C.

World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.

30.

[Do postoperative drainage types modify outcomes after retrograde intrarenal surgery?].

Cerruti A, Lebdai S, Martin F, Hoarau N, Chautard D, Culty T, Azzouzi AR, Bigot P.

Prog Urol. 2015 May;25(6):331-5. doi: 10.1016/j.purol.2015.01.017. Epub 2015 Mar 5. French.

PMID:
25748790
31.

Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.

Lebdai S, Villers A, Barret E, Nedelcu C, Bigot P, Azzouzi AR.

World J Urol. 2015 Jul;33(7):965-71. doi: 10.1007/s00345-015-1493-8. Epub 2015 Jan 23.

PMID:
25614256
32.

[Evaluation of the impact of CTMH guidelines on the management of benign prostatic hyperplasia].

Lebdai S, Rahmène Azzouzi A, Delongchamps NB, Benchikh A, Campeggi A, Cornu JN, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2015 Jan;25(1):47-53. doi: 10.1016/j.purol.2014.09.049. French.

PMID:
25453357
33.

Post-treatment MRI aspects of photodynamic therapy for prostate cancer.

Kulik M, Nedelcu C, Martin F, Lebdai S, Rousselet MC, Azzouzi AR, Aubé C.

Insights Imaging. 2014 Dec;5(6):697-713. doi: 10.1007/s13244-014-0359-8. Epub 2014 Oct 7.

34.

[Predictable access to the fellowship of urology in France till 2016: an update of the AFUF].

Celhay O, Brichart N, Audenet F, Capon G, Dariane C, Fiard G, Lebdai S, Madec FX, Maurin C, Sanson S, Rizk J, Tanchoux C, Thibault F, Terrasa JB, Murez T, Terrier JÉ.

Prog Urol. 2014 Sep;24(10):658-64. doi: 10.1016/j.purol.2014.04.004. Epub 2014 Jun 2. French.

PMID:
25214296
35.

[Conservative treatment of male non-neurologic urinary incontinence: a review by the LUTS committee of the French Urological Association].

Lebdai S, Delongchamps NB, Azzouzi AR, Benchikh A, Campeggi A, Cornu JN, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2014 Sep;24(10):610-5. doi: 10.1016/j.purol.2014.01.003. Epub 2014 Feb 14. Review. French.

PMID:
25214288
36.

[Management of benign prostate hyperplasia].

Lebdai S, Descazeaud A; Et les membres du CTMH de l’AFU.

Prog Urol. 2014 Nov;24(14):929-33. doi: 10.1016/j.purol.2014.07.010. Epub 2014 Sep 8. French.

PMID:
25199729
37.

[Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].

Lebdai S, Martin F, Bigot P, Azzouzi AR.

Prog Urol. 2014 Nov;24(14):911-4. doi: 10.1016/j.purol.2014.08.002. Epub 2014 Sep 5. French.

PMID:
25195031
38.

Identification and validation of TGFBI as a promising prognosis marker of clear cell renal cell carcinoma.

Lebdai S, Verhoest G, Parikh H, Jacquet SF, Bensalah K, Chautard D, Rioux Leclercq N, Azzouzi AR, Bigot P.

Urol Oncol. 2015 Feb;33(2):69.e11-8. doi: 10.1016/j.urolonc.2014.06.005. Epub 2014 Jul 14.

PMID:
25035170
39.

[Treatment of non-neurogenic masculine urinary incontinence due to overactive bladder: a review by the LUTS committee of the French Urological Association].

Lebdai S, Haillot O, Azzouzi AR, Benchikh A, Campeggi A, Cornu JN, Delongchamps NB, Dumonceau O, Faix A, Fourmarier M, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2014 Jul;24(9):588-94. doi: 10.1016/j.purol.2014.01.002. Epub 2014 Feb 10. Review. French.

PMID:
24975794
40.

[Current state of compensation of on-duty and on-call urologists in France: a study from AFUF].

Dariane C, Rizk J, Meyer F, Audenet F, Brichart N, Capon G, Fiard G, Lebdai S, Madec FX, Maurin C, Murez T, Sanson S, Tanchoux C, Terrasa JB, Thibault F, Terrier JE.

Prog Urol. 2014 Jun;24(7):456-62. doi: 10.1016/j.purol.2013.11.009. Epub 2013 Dec 27. French.

PMID:
24861686
41.

[Initial assessment of male non-neurogenic incontinence: systematic review of the literature by the LUTS committee of the French Urological Association].

Mathieu R, Benchikh A, Azzouzi AR, Campeggi A, Cornu JN, Delongchamps NB, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lebdai S, Lukacs B, Misrai V, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2014 Jun;24(7):421-6. doi: 10.1016/j.purol.2013.11.011. Epub 2013 Dec 25. Review. French.

PMID:
24861681
42.

[The role of simulation in the curriculum of French urologists-in-training: a study by the French Association of Urologists-in-Training (AFUF)].

Fiard G, Capon G, Rizk J, Maurin C, Dariane C, Audenet F, Tanchoux C, Brichart N, Lebdai S, Sanson S, Madec FX, Thibault F, Terrasa JB, Murez T, Terrier JE.

Prog Urol. 2014 May;24(6):390-6. doi: 10.1016/j.purol.2013.10.013. Epub 2013 Dec 2. French.

PMID:
24821563
43.

[Research fellowship in the curriculum of French urologists-in-training: a study by the French Association of Urologists-in-training (AFUF)].

Rizk J, Audenet F, Brichart N, Capon G, Dariane C, Fiard G, Lebdai S, Madec FX, Maurin C, Sanson S, Tanchoux C, Thibault F, Murez T, Terrasa JB, Terrier JÉ.

Prog Urol. 2014 May;24(6):359-66. doi: 10.1016/j.purol.2013.10.012. Epub 2013 Nov 27. French.

PMID:
24821559
44.

[Clinical impact of the intravesical prostatic protrusion: a review by the LUTS committee of the French Urological Association].

Lebdai S, Ammi M, Bigot P, Cornu JN, Mathieu R, Descazeaud A, Azzouzi AR; CTMH.

Prog Urol. 2014 Apr;24(5):313-8. doi: 10.1016/j.purol.2013.09.009. Epub 2013 Oct 23. Review. French.

PMID:
24674338
45.

Double-J ureteral stent under local anesthesia for women.

Carrouget J, Ammi M, Lasocki S, Lebdai S, Brassart E, Geslin D, Larre S, Culty T, Chautard D, Azzouzi AR, Bigot P.

Can J Urol. 2014 Feb;21(1):7120-4.

PMID:
24529012
46.

[Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].

Neuzillet Y, Flamand V, Lebdai S, Villers A, Lebret T.

Prog Urol. 2013 Oct;23 Suppl 1:S34-43. doi: 10.1016/S1166-7087(13)70044-7. Review. French.

PMID:
24314737
47.

[Corticotherapy in castration-resistant prostate cancer].

Lebdai S, Branchereau J, Robert G, De La Taille A, Bouchaert P.

Prog Urol. 2013 Oct;23 Suppl 1:S23-33. doi: 10.1016/S1166-7087(13)70043-5. Review. French.

PMID:
24314736
48.

Nephron-sparing surgery for renal tumors measuring more than 7 cm: morbidity, and functional and oncological outcomes.

Bigot P, Hétet JF, Bernhard JC, Fardoun T, Audenet F, Xylinas E, Ploussard G, Pignot G, Bessede T, Ouzaid I, Robine E, Brureau L, Merigot de Treigny O, Maurin C, Long JA, Rouffilange J, Hoarau N, Lebdai S, Rouprêt M, Bastien L, Neuzillet Y, Mongiat-Artus P, Verhoest G, Zerbib M, Ravery V, Rigaud J, Bellec L, Baumert H, Chautard D, Bensalah K, Escudier B, Paparel P, Grenier N, Rioux-Leclercq N, Azzouzi AR, Soulié M, Patard JJ.

Clin Genitourin Cancer. 2014 Feb;12(1):e19-27. doi: 10.1016/j.clgc.2013.09.004. Epub 2013 Sep 28.

PMID:
24210610
49.

Prostate-specific antigen evolution after photoselective vaporization of the prostate.

Lebdai S, Prezelin Y, Pereira H, Bruyere F.

J Endourol. 2014 Mar;28(3):347-52. doi: 10.1089/end.2013.0522. Epub 2013 Dec 3.

PMID:
24156628
50.

Impact of lower pole calculi in patients undergoing retrograde intrarenal surgery.

Martin F, Hoarau N, Lebdai S, Pichon T, Chautard D, Culty T, Azzouzi AR, Bigot P.

J Endourol. 2014 Feb;28(2):141-5. doi: 10.1089/end.2013.0515. Epub 2013 Nov 5.

PMID:
24063300

Supplemental Content

Loading ...
Support Center